Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Mineralocorticoid receptor antagonists confer antiproteinuric effect in CKD

13 Dec 2019

Treatment with mineralocorticoid receptor antagonists (MRA) alone or in addition to renin–angiotensin system (RAS) blockade is associated with significant antiproteinuric effects, with a slight increase in mean potassium levels, in patients with chronic kidney disease (CKD), a study has shown.

A systematic review and meta-analysis was conducted to determine the effects of MRAs on albuminuria/proteinuria and adverse events, such as change in renal function and hyperkalaemia incidence. The investigators searched electronic databases, clinical trial registries and grey literature to retrieve randomized controlled trials (RCTs) that compared MRA alone or on top of RAS blockade with placebo or active treatment.

Forty-five studies with a total of 2,767 participants were initially identified, of which 31 were included in the analysis.

Compared with placebo, MRAs (alone or with RAS blockade) reduced urine albumin-to-creatinine ratio (UACR) by –24.55 percent (95 percent confidence interval [CI], –29.57 to –19.53 percent), urine protein-to-creatinine ratio by –53.93 percent (95 percent CI, –79 to –28.86 percent) and 24-h albumin excretion by –32.47 percent (95 percent CI, –41.1 to –23.85 percent).

MRAs, compared with calcium-channel blockers, also reduced UACR by –22.48 percent (95 percent CI, –24.51 to –20.44 percent), but there were no differences when compared with a second RAS blockade or nonpotassium-sparing diuretics.

The addition of an MRA resulted in a change in estimated glomerular filtration rate of –2.38 ml/min per 1.73 m2 (95 percent CI, −3.51 to −1.25), an increase in potassium by 0.22 mEq/l (95 percent CI, 0.16–0.28 mEq/l) and a 2.6-fold rise in the risk of hyperkalaemia (risk ratio, 2.63, 95 percent CI, 1.69–4.08) compared with placebo or active control.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.